• The goal of this clinical research study is to learn if docetaxel, cisplatin, and 5-fluorouracil in combination can help to control the disease in patients with cancer of the paranasal sinuses. [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
  

Inclusion Criteria:

1. Patients with cytologic or histological diagnosis of squamous cell carcinoma or poorly differentiated carcinoma of the nasal cavity and paranasal sinuses.
2. 2. Stage II-IV disease; T 2-4, N any, M0. Measurable disease is required with the following criteria: Measurable lesions can be accurately measured, with at least one diameter >\= 1.0 cm by spiral CT scan or MRI. Lesions can be bidimensionally measurable or unidimensionally measurable. Every effort should be made to measure lesions in two dimensions. Measurable disease is present if the patient has one or more measurable lesions. Non-measurable lesions/disease are all other lesions, including small lesions (those with measurements < 2.0 cm; or < 1.0 cm with spiral CT).
3. Karnofsky performance status of >\= 70 or ECOG PS 0-2.
4. Age > 16 years.
5. Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3 and platelet count of >/= 140,000 cells/mm3;
6. Hepatic Parameters: Total Bilirubin </= ULN AST and ALT and Alkaline Phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used. **Refer to table in protocol pg.6**
7. Hemoglobin >/= 10.0g/dL
8. Creatinine clearance > 50 ml/min determined by 24 hour collection or nomogram: CrCl male = (140 - age) x (wt in kg)/serum Cr x 72 CrCl female = 0.85 x (CrCl male)
9. Patients should have no debilitating acute or chronic co-morbid condition, or acute serious infection that in the opinion of the attending medical oncologist would preclude safe administration of the prescribed chemotherapy treatment.
10. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication.
11. Patients must sign a study-specific informed consent form.

Exclusion Criteria:

1. Histology other than squamous cell or poorly differentiated carcinoma.
2. Evidence of distant metastases (below the clavicle) by clinical or radiographic measures.
3. Karnofsky performance status < 70 or ECOG>2 (Appendices B and BB).
4. Pre-existing peripheral neuropathy CTCAE grade 2 or worse or pre-existing severe bilateral hearing deficits.
5. Prior chemotherapy, within the previous 3 years.
6. Prior radiotherapy to the paranasal sinus region or the upper neck.
7. Initial surgical resection rendering the patient clinically and radiologically disease free.
8. Simultaneous primary invasive cancers.
9. Patients with a past history of malignancy (excluding non melanoma skin cancers, and cancers treated > 3 years prior for which patient remains continuously disease free).
10. Men and Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 3 months after the study. Subjects who are men must also agree to use effective contraception. Note: WOCBP must be using an adequate method of contraception throughout the study and for up to 3 months after the study. Adequate methods of contraception will include (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
11. Women who are pregnant or breastfeeding.
12. Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.